Drug for one hepatitis type may activate another: watchdog

hepatitis C
Electron micrographs of hepatitis C virus purified from cell culture. Scale bar is 50 nanometers. Credit: Center for the Study of Hepatitis C, The Rockefeller University.
Drugs against one type of hepatitis may activate another, sometimes with fatal consequences, Europe's medicines watchdog warned on Friday.

The medicines, which are highly effective against C, may trigger latent hepatitis B in patients infected with both types, the European Medicines Agency said in a statement.

It named the antivirals Daklinza, Exviera, Harvoni, Olysio, Sovaldi and Viekirax used to treat C, an infectious liver disease.

"Cases of the return of previously inactive hepatitis B infection, which can be fatal, have been reported in patients treated," with this class of drug, the agency said in a statement announcing the findings of a probe.

There have been only about 30 cases of hepatitis B reactivation out of thousands of patients taking the drugs, the agency said. And there was not enough information to draw a conclusion on cancer risk.

But a special risk assessment committee of the agency recommended that all be screened for hepatitis B virus before starting any of these treatments.

It also proposed that a warning be included in the drug information leaflet.

The drugs, a new class known as "direct-acting antivirals" are more effective than their predecessors.

At a cost of some 40,000 to 80,000 euros ($43,000-$86,000) for a 12-week course, they are the preserve of a lucky few.

Hepatitis is an inflammation of the liver, most often caused by a virus but sometimes by drug or alcohol abuse, other infections, or autoimmune diseases.

The B and C types usually occur from contact with of an infected person. Other than for hepatitis B, there is no vaccine against hepatitis C.


Explore further

New tests for choosing right hep C drug could save money (Update)

© 2016 AFP

Citation: Drug for one hepatitis type may activate another: watchdog (2016, December 2) retrieved 18 July 2019 from https://medicalxpress.com/news/2016-12-drug-hepatitis-watchdog.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
47 shares

Feedback to editors

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more